Abcellera Biologics Inc ABCL

$11.18 -0.31 (-2.70%)

Valuation

Market cap
3,752,841,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
1,505,744
Avg volume
4,299,200
Day's range
$11.03 – $11.44
Shares out
326,618,000
Stochastic %K
33%
Beta
1.59
Analysts
Strong Buy
Price target
$17.92

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

maestrodarkhorse Nov 16, 7:23 PM
$ABCL Carl Hansen mentioned the DTC (Direct-to-Consumer) approach for the first time at this Jefferies Conference. It seems he sees a direct-to-consumer sales strategy for Abcl 635, like those used for Wegovy and Mounjaro, as advantageous for a young biotech company with a weak sales force.
0 replies
maestrodarkhorse Nov 16, 7:21 PM
$ABCL $ABCL Piper Sandler analyst Allison Bratzel raised the firm's price target on AbCellera to $20 from $12 and keeps an Overweight rating on the shares. With Q3 reporting largely wrapped up, the firm is updating estimates.
0 replies
TradeWinner Nov 16, 6:43 PM
$ABCL added some shares down here in the low 11s.
0 replies
JohnnyBoy272 Nov 16, 6:41 PM
$CABA I have sold all my shares, better opportunities in the market, will only invest once management spends a single dime at this price. I have reached out multiple times, but they have ignored me, sadly, any time IR ignores simple questions about financing always turns out in a year their stock drops another 50%+. Sold and bought $ABCL
2 replies
DeMampCamp Nov 16, 6:08 PM
$ABCL I'd say it's holding up pretty damn well considering the rest of the markets, let's just keep >$11 and I'll be sleep ok at night! Cheers and happy Monday, all!
0 replies
Robbindalle Nov 16, 5:25 PM
$ABCL Carl sound Incredible confident speaking about the Future for AbCellera. I think the stock will reflect the bright future ahead. Have owned this since 2021 looking forward to another 5 years.
0 replies
PaloPB Nov 16, 3:16 PM
$ABCL some good news
0 replies
Buying_Low_Selling_High Nov 16, 2:53 PM
$ABCL upcoming ANT IPO and the $NVDA drama are shifting the attention away from Abcellera but it will soon be over and green days will be back.
0 replies